How an inhibitor of the HIV-I protease modulates proteasome activity
G Schmidtke, HG Holzhutter, M Bogyo, N Kairies… - Journal of Biological …, 1999 - ASBMB
The human immunodeficiency virus, type I protease inhibitor Ritonavir has been used
successfully in AIDS therapy for 4 years. Clinical observations suggested that Ritonavir may
exert a direct effect on the immune system unrelated to inhibition of the human
immunodeficiency virus, type I protease. In fact, Ritonavir inhibited the major
histocompatibility complex class I restricted presentation of several viral antigens at
therapeutically relevant concentrations (5 μm). In search of a molecular target we found that …
successfully in AIDS therapy for 4 years. Clinical observations suggested that Ritonavir may
exert a direct effect on the immune system unrelated to inhibition of the human
immunodeficiency virus, type I protease. In fact, Ritonavir inhibited the major
histocompatibility complex class I restricted presentation of several viral antigens at
therapeutically relevant concentrations (5 μm). In search of a molecular target we found that …